VERASTEM INC (VSTM)
Health Care · Oncology / RAS/MAPK pathway-targeted small-molecule therapeutics · NASDAQ
A biopharmaceutical company developing targeted therapies for RAS/MAPK pathway-driven cancers, with a newly FDA-approved combination treatment for KRAS-mutated ovarian cancer and a pipeline focused on direct KRAS G12D inhibition.
What VERASTEM INC does
Verastem Inc. is a biopharmaceutical company developing and commercializing therapies that target RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib), approved by the FDA in May 2025 for adults with KRAS-mutated recurrent low-grade serous ovarian cancer. The pipeline includes VS-7375, a selective oral KRAS G12D dual ON/OFF inhibitor in Phase 1/2 development for pancreatic, lung, and colorectal cancers, along with additional programs targeting FAK inhibition and partnered early-stage assets through GenFleet Therapeutics.
Themes: ["KRAS-targeted oncology"]
Fundamentals
- Price$5.40 as of 2026-07-09 close
- Market cap$422M as of 2026-07-10
- 1-year return+12.3% as of 2026-07-09 close
- Net margin-391.2% as of 2026-07-10
- Gross margin+85.1% as of 2026-07-10
- ROE-163.6% as of 2026-07-10
- Debt / equity1.01 as of 2026-07-10
- Revenue growth (YoY)+209.1% as of 2026-07-10
- Revenue CAGR (3y)+97.0% SEC XBRL
- Beta0.40 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.